Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NCInternational Journal of Cancer

Follow‐Up and Outcomes After Thermal Ablation Treatment Among HIV ‐Infected Women From Resource‐Limited Countries With Positive HPV ‐Based Screening: Results of the AIMA ‐ CC Cohort ( ANRS 12375)

7 more authors

Abstract

Primary screening for human papillomavirus (HPV) followed by treatment with thermal ablation (TA) is an important component of the global strategy to eliminate cervical cancer. However, evidence on post‐TA outcomes in women living with HIV (WLWH) remains limited. The aim of this study is to evaluate the risk and determinants of post‐TA CIN2+. As part of the AIMA‐CC study, WLWH from Côte d'Ivoire, Burkina Faso and Cambodia were screened using HPV testing (GeneXpert). All HPV‐positive women were biopsied and those with positive triage (positive visual inspection and/or HPV‐161845) were treated with TA using a flat probe and followed for 12 months with HPV testing and biopsies. Among the 456 WLWH (age: 30–59 years) treated with TA and with valid histology, 396 (86%) attended the 12‐month follow‐up visit. HPV persistence (HPV of same GeneXpert channel at baseline and 12‐month post‐treatment) was 40% and was associated with baseline HPV16 positivity ( p = 0.007), age ≥ 40 years ( p = 0.03) and CD4 ≤ 500 cells/mm 3 ( p = 0.02). CIN2+ was detected at 12 months in 12 (4%) of the 318 WLWH with valid histology and was associated with 12‐month HPV positivity (OR: 5.29 [1.46–28.46]). The risk of CIN2+ was particularly high among women with HPV‐16 at 12 months (OR: 15.53 [3.49–91.17]). HPV positivity at 12 months had a sensitivity for detecting CIN2+ of 83% but a specificity of 54%. HPV‐16 positivity had lower sensitivity (42%) but high specificity (> 90%). In conclusion, there is an urgent need to improve TA management in WLWH who are at high risk of CIN2+ re‐occurrence post‐treatment.

Related

  1. Long-term outcomes of vascularized fibular grafting for infected non-union of the lower limb: a competing-risk analysis
    Anne Le Hir, Piseth Seng, David Delarbre +4
    Journal of Bone and Joint InfectionPeer-reviewedCC BY 4.0Full textMicrobiologyCardiovascular medicineHAL
  2. Viral disease outcomes are indistinguishable between experimentally infected bats and rodents
    Maxwell J. Farrell, Samantha K. Tucker, Nardus Mollentze +1
    PLOS BiologyPeer-reviewedCC BY 4.0Full textEvolutionary biologyMicrobiologyPLOS
  3. Alternative digital secondary education for marginalized, out-of-school youth in low- and middle-income countries: Protocol for a scoping review of intervention models, outcomes, and implementation challenges
    Jefferson Mwaisaka, Lilian Agesa, Ruth Nanjekho
    PLOS OnePeer-reviewedCC BY 4.0Full textNeuroscienceGeneral earth sciencePLOSPMC
  4. F-OGS, a new “Follow-up Onco-Geriatric Screening” tool during the follow-up of older patients undergoing oncological treatment. Pilot study of feasibility and acceptability
    Simon Valero, Anaïs Fazilleau, Joe de Keizer +5
    Journal of Geriatric OncologyPeer-reviewedLicence not stated1 citedGeneral biologyOncologyHAL
  5. Childhood Trauma and Transdiagnostic Mental Health Outcomes Among Adults in 17 Arab Countries: A Multinational Cross-Sectional Study Using a Latent Global Trauma Model
    K. M. Al-Dhayani, B. A. Osman, D. M. Elrayah +11
    bioRxivPreprintCC BYFull textNeurosciencebioRxiv
BibTeX
@article{debeaudrap2026followup,
  title = {{Follow‐Up and Outcomes After Thermal Ablation Treatment Among HIV ‐Infected Women From Resource‐Limited Countries With Positive HPV ‐Based Screening: Results of the AIMA ‐ CC Cohort ( ANRS 12375)}},
  author = {Pierre Debeaudrap and Firmin Nongodo Kabore and Limsreng Setha and Joseph Tegbe and Brahima Doukoure and Moeung Sotheara and Olivier Segeral and Korn Aun and Eugène Messou and Matthieu Chicaud and Kim Sothea and Pierre Vassilakos and Armel Poda and Evelyne Kasilé Poda and Antoine Jaquet and Adolphe Some and Patrick Petignat and Gary Clifford and Apollinaire Horo},
  journal = {International Journal of Cancer},
  year = {2026},
  month = jul,
  doi = {10.1002/ijc.70648},
  url = {https://hal.science/hal-05766887v1},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Follow‐Up and Outcomes After Thermal Ablation Treatment Among HIV ‐Infected Women From Resource‐Limited Countries With Positive HPV ‐Based Screening: Results of the AIMA ‐ CC Cohort ( ANRS 12375)
AU  - Pierre Debeaudrap
AU  - Firmin Nongodo Kabore
AU  - Limsreng Setha
AU  - Joseph Tegbe
AU  - Brahima Doukoure
AU  - Moeung Sotheara
AU  - Olivier Segeral
AU  - Korn Aun
AU  - Eugène Messou
AU  - Matthieu Chicaud
AU  - Kim Sothea
AU  - Pierre Vassilakos
AU  - Armel Poda
AU  - Evelyne Kasilé Poda
AU  - Antoine Jaquet
AU  - Adolphe Some
AU  - Patrick Petignat
AU  - Gary Clifford
AU  - Apollinaire Horo
PY  - 2026
DA  - 2026/07/15
JO  - International Journal of Cancer
DO  - 10.1002/ijc.70648
UR  - https://hal.science/hal-05766887v1
AB  - Primary screening for human papillomavirus (HPV) followed by treatment with thermal ablation (TA) is an important component of the global strategy to eliminate cervical cancer. However, evidence on post‐TA outcomes in women living with HIV (WLWH) remains limited. The aim of this study is to evaluate the risk and determinants of post‐TA CIN2+. As part of the AIMA‐CC study, WLWH from Côte d'Ivoire, Burkina Faso and Cambodia were screened using HPV testing (GeneXpert). All HPV‐positive women were biopsied and those with positive triage (positive visual inspection and/or HPV‐161845) were treated with TA using a flat probe and followed for 12 months with HPV testing and biopsies. Among the 456 WLWH (age: 30–59 years) treated with TA and with valid histology, 396 (86%) attended the 12‐month follow‐up visit. HPV persistence (HPV of same GeneXpert channel at baseline and 12‐month post‐treatment) was 40% and was associated with baseline HPV16 positivity ( p = 0.007), age ≥ 40 years ( p = 0.03) and CD4 ≤ 500 cells/mm 3 ( p = 0.02). CIN2+ was detected at 12 months in 12 (4%) of the 318 WLWH with valid histology and was associated with 12‐month HPV positivity (OR: 5.29 [1.46–28.46]). The risk of CIN2+ was particularly high among women with HPV‐16 at 12 months (OR: 15.53 [3.49–91.17]). HPV positivity at 12 months had a sensitivity for detecting CIN2+ of 83% but a specificity of 54%. HPV‐16 positivity had lower sensitivity (42%) but high specificity (> 90%). In conclusion, there is an urgent need to improve TA management in WLWH who are at high risk of CIN2+ re‐occurrence post‐treatment.
SN  - 0020-7136
SN  - 1097-0215
ER  -